drugset / Trial / NCT02242409
Study of Gemcitabine and Abraxane for Pancreas Cancer
NaSingle-groupOpen-labelTreatment
Summary
A Phase II trial of gemcitabine plus nab-paclitaxel in the second line setting
Timeline
- Start
- 2014-09
- Primary completion
- 2016-12
- Completion
- 2016-12
Outcome
Outcome not reported
Stopped: “Testing of combination no longer relevant”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |